PFS
DSGN icon

Prospera Financial Services’s Design Therapeutics DSGN Stock Holding History

Prospera Financial Services’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,404
Closed -$23K – 1854
2022
Q1 		$23K Buy
+1,404
New +$21.5K ﹤0.01% 1674

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Prospera Financial Services's DSGN Position: Q2 2022 in Review

Prospera Financial Services sold out of Design Therapeutics (DSGN) in Q2 2022, closing a stake of 1,404 shares — an estimated $23K sold.

Prospera Financial Services first reported a position in DSGN in Q1 2022 and held it in 1 quarter. The position peaked at $23K in Q1 2022. 74 funds tracked by Wall St. Rank hold DSGN as of Q2 2022.

  • Prospera Financial Services reported no remaining Design Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Prospera Financial Services sold 1,404 Design Therapeutics shares in Q2 2022, an estimated $23K.
  • Prospera Financial Services first reported a position in Design Therapeutics in Q1 2022 and held it in 1 quarter.
  • Prospera Financial Services's Design Therapeutics position peaked at $23K in Q1 2022.
  • 74 funds tracked by Wall St. Rank held Design Therapeutics as of Q2 2022.

Based on Prospera Financial Services's 13F filing for Q2 2022, filed 8 Aug 2022.